Mounjaro (tirzepatide) works by activating both GLP-1 and GIP receptors at the same time, which helps your body release more insulin when blood sugar is high, lowers glucagon, slows gastric emptying, and reduces appetite. That dual action is why it can improve blood sugar control and support weight loss.
For adults in the UK with type 2 diabetes, or those exploring prescription weight-management treatment, especially if diet, exercise, or other treatments have not been enough, understanding that mechanism helps explain who Mounjaro may suit and what results to expect.
This guide covers what it does in the body, how its effects on blood sugar and weight develop over time, who can use it, key safety points, how it compares with Ozempic, and why treatment still works best alongside diet and exercise.
The Dual Action: GIP and GLP-1
Your gut naturally releases hormones called incretins when you eat, which help control blood sugar and appetite. Two of the most important are GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide).
Most incretin-based medicines, including semaglutide (Ozempic and Wegovy), act on GLP-1 alone. Tirzepatide acts on both GLP-1 and GIP. It is a single molecule that switches on both receptor systems, which is what "dual agonist" means. Working through both pathways may contribute to greater reductions in blood sugar and body weight than have been observed with some GLP-1 receptor agonists in clinical studies.
What It Does to Blood Sugar
Mounjaro lowers blood sugar levels through several coordinated effects, all of which mirror what your body's own hormones do.
It boosts insulin, mainly when blood sugar is raised. This is the important part. Tirzepatide increases insulin release from the pancreas in a glucose-dependent way. Its insulin-stimulating effect is glucose-dependent, so the risk of hypoglycaemia is lower when tirzepatide is used alone. Because of this, tirzepatide on its own rarely causes blood sugar to drop too low.
It reduces glucagon. Glucagon is a hormone that tells the liver to release stored glucose. In type 2 diabetes this can happen inappropriately, pushing blood sugar up. Tirzepatide reduces this effect, again in a glucose-dependent way, so the liver releases less glucose when it is not needed.
It slows gastric emptying. By slowing how quickly food leaves the stomach, it may reduce the spike in blood sugar after eating, and make post-meal glucose levels more gradual.
Together these lower average blood sugar, which is why tirzepatide produces meaningful reductions in HbA1c (a measure of longer-term blood sugar control) in people with type 2 diabetes, improving blood sugar levels with a low risk of hypoglycaemia when used on its own.
The Blood Sugar Safety Point That Matters
The hypoglycaemia risk matters most when Mounjaro is combined with certain other diabetes medicines.
On its own, Mounjaro rarely causes low blood sugar (hypoglycaemia), because of the glucose-dependent mechanism above. But the risk rises significantly if you take it alongside insulin or a sulfonylurea (medicines such as gliclazide). Those medicines lower blood sugar regardless of your glucose level, and adding tirzepatide on top can push it too low. That low-hypo risk point is separate from broader side effects.
What this means in practice:
- If you take insulin or a sulfonylurea, your prescriber may reduce the dose of those when you start Mounjaro, and you should monitor your blood sugar more closely, especially early on. Insulin should be reduced in a stepwise way under guidance.
- If you take metformin or an SGLT2 inhibitor, the existing dose can generally be continued when tirzepatide is added.
- Never adjust your insulin or other diabetes medicines yourself. Any changes are made with your prescriber or diabetes team.
It is worth knowing the signs of low blood sugar if you are on these combinations: shakiness, sweating, dizziness, confusion, hunger, a fast heartbeat, irritability or blurred vision. Treat it promptly with fast-acting sugar and tell your healthcare team if it happens.
How It Helps With Weight
The same dual action that lowers blood sugar also reduces appetite. GLP-1 and GIP receptors sit not only in the pancreas and gut but in the parts of the brain that control hunger and fullness.
By acting there, tirzepatide reduces appetite and quietens food cravings, and combined with slower stomach emptying, you feel full sooner and for longer. In clinical studies, some participants receiving tirzepatide achieved around 20% average weight loss under trial conditions, which helps show how much weight treatment can shift when reduced appetite makes it easier to lose weight and cut excess weight.
In a 72-week weight-management trial, average weight loss approached 20% with higher tirzepatide doses.
This is a genuine hormonal effect on appetite, not a stimulant. Eating less then supports both weight loss and blood sugar control, which is why the two benefits reinforce each other.
What Is Known About Tirzepatide and Pancreatic Function?
You may see claims that tirzepatide "preserves" or "protects" the insulin-producing beta cells of the pancreas. There is laboratory and early clinical evidence suggesting incretin medicines may support beta-cell function, but whether this translates into lasting protection in people is not firmly established. It is a plausible potential benefit, not a proven promise, and it is not a reason to choose treatment on its own. The established benefits are the blood-sugar and weight effects above.
Who Is Mounjaro For?
Mounjaro has two licensed uses in the UK: type 2 diabetes, and weight management. This is worth knowing, because it is licensed for both, unlike some alternatives. It may be available through NHS services for some eligible patients, and a private prescription may also be appropriate in the UK depending on your circumstances and access route for a mounjaro prescription.
For type 2 diabetes, NICE recommends tirzepatide for certain adults when triple therapy with metformin and two other oral antidiabetic medicines is ineffective, not tolerated or contraindicated, and specific BMI and clinical criteria are met. It is used alongside diet and exercise.
For weight management, the licensed criteria are a BMI of 30 or above, or 27 or above with weight-related medical conditions such as high blood pressure, sleep apnoea, cardiovascular disease, prediabetes, type 2 diabetes or high cholesterol.
Prediabetes and insulin resistance: Mounjaro is not specifically licensed to treat prediabetes as a condition, but people with prediabetes who meet the weight-management criteria may be eligible via that route, and weight loss itself improves insulin resistance. Whether it is appropriate is a decision for a prescriber. Availability through NHS services may vary across the UK nations and local health systems.
It should not be used during pregnancy and is not recommended when planning pregnancy. If you are breastfeeding, discuss whether treatment is appropriate with your healthcare professional.
If you have concerns about thyroid disease or a history of thyroid tumours, tell your prescriber so they can assess whether Mounjaro is appropriate.
If you have had pancreatitis, tell your prescriber, as tirzepatide should be used with caution in this situation. Mounjaro is not licensed for weight management in people under 18.
In animal studies, tirzepatide was associated with thyroid C-cell tumours. The relevance of this finding to humans has not been established, but the precaution remains important, which is why this caution is taken seriously.
If you use the contraceptive pill, tirzepatide may affect oral contraceptive exposure when treatment is started and after dose increases, so additional contraceptive precautions may be recommended.
If you have existing diabetic eye disease (retinopathy), tell your prescriber, because rapid improvements in blood sugar can temporarily affect it and may need monitoring.
How Quickly Does Mounjaro Work?
Blood sugar levels can start improving after treatment begins, while the full effect on HbA1c develops over time as the dose is increased. Appetite changes can also occur early in treatment, while weight loss develops gradually over time.
Appetite changes are often noticed within the first few weeks. Weight loss builds gradually over months rather than appearing immediately. Because the dose starts low at the starting dose and steps up over time, the effect strengthens as you progress through the strengths under your prescriber's guidance.
Does It Work Without Diet and Exercise?
Mounjaro is licensed and proven to work alongside a reduced-calorie diet and increased physical activity, and that is how it was studied. It can make it easier to eat less by reducing appetite, so some weight-loss effect can occur even without major lifestyle changes.
Weight loss medicine works best with lifestyle support, and after stopping treatment, some weight regain is common.
But the results are better and more durable when paired with dietary and lifestyle changes, and for diabetes in particular, diet and activity remain central to management. It is a powerful tool, not a replacement for the basics.
Mounjaro vs Ozempic: How They Differ
Since people compare the two, here is the mechanistic difference, accurately.
- Mounjaro (tirzepatide) acts on both GLP-1 and GIP receptors (dual agonist).
- Ozempic (semaglutide) acts on GLP-1 only.
Both lower blood sugar and reduce appetite through overlapping mechanisms, but clinical studies have shown greater average reductions in blood sugar and body weight than have been reported with some comparator treatments in head-to-head data, including head-to-head studies that reported greater average weight loss with tirzepatide than with semaglutide.
A licensing point worth getting right: Ozempic is licensed for type 2 diabetes, while Wegovy is the semaglutide brand licensed for weight management in the UK. Using Ozempic specifically for weight management would therefore be outside its licensed indication.
Which medicine suits you is a clinical decision, not one to make on mechanism alone. Our guide to prescription weight loss treatments sets out the options.
Key Takeaways
- Tirzepatide is a dual agonist: it acts on both GLP-1 and GIP, unlike GLP-1-only medicines.
- It lowers blood sugar by boosting insulin (glucose-dependently), cutting glucagon, and slowing gastric emptying.
- On its own it rarely causes low blood sugar, but the risk rises with insulin or a sulfonylurea.
- Those medicines may need dose reduction and closer monitoring, never self-adjust.
- It affects appetite through hormonal pathways, supporting weight loss.
- It is licensed in the UK for type 2 diabetes and weight management. NHS access for weight management is subject to eligibility and implementation criteria.
- It works best alongside diet and activity, not instead of them.
Medical Disclaimer
This guide is for general information only and is not a substitute for medical advice, diagnosis or treatment from a qualified healthcare professional. Mounjaro (tirzepatide) is a prescription-only medicine and should only be used under the supervision of a qualified prescriber. Its suitability, dosage and treatment plan vary between individuals. Always follow your prescriber's instructions and the patient information leaflet. If you have diabetes, take insulin or a sulfonylurea, are pregnant or breastfeeding, or have other medical conditions or concerns about Mounjaro, speak with your doctor, pharmacist or diabetes team before starting or changing treatment. Do not change or stop your medication without medical advice.
